Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
| العنوان: | Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia |
|---|---|
| المؤلفون: | Anir Enkhbat, Bali Pulendran, Emily Haraguchi, Zulkhuu Genden, Altankhuu Mordorj, Prabhu S. Arunachalam, Dahgwahdorj Yagaanbuyant, Scott D. Boyd, Daniel Solis, Anthony S. Buzzanco, Mihir Shah, Delgersaikhan Zulkhuu, Kari C. Nadeau, Nomin Ariungerel, Hannah Wang, Ganbold Dalantai, Tungalag Khurelsukh, Sharon Chinthrajah, Malaya K. Sahoo, Purevjargal Bat-Ulzii, James J. Y. Liu, Benjamin A. Pinsky, Jacob N. Wohlstadter, Naranbaatar Dashdorj, Mamdouh Sibai, George Sigal, Theodore S. Jardetzky, Natsagdorj Burged, James L. Wilbur, Odgerel Oidovsambuu, Sumiya Byambabaatar, Uurtsaikh Baatarsuren, Naranjargal Dashdorj, Jacob A. Miller, Katharina Röltgen, Byambasuren Ochirsum, Oliver F. Wirz, Andreas Bungert, Alexandra S. Lee, Enkhtuul Batbold |
| المصدر: | Cell Host & Microbe |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Gene Expression, Antibody level, Biology, Antibodies, Viral, Microbiology, Mass Vaccination, Serology, Immunogenicity, Vaccine, Virology, ChAdOx1 nCoV-19, Humans, BNT162 Vaccine, Aged, Retrospective Studies, SARS-CoV-2, Brief Report, Immune Sera, Antibody titer, COVID-19, Mongolia, Middle Aged, Vaccination, Antibody response, biology.protein, Parasitology, Female, Angiotensin-Converting Enzyme 2, Antibody |
| الوصف: | Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins reveal marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide. Graphical Abstract Dashdorj et al. examined antibody responses in COVID-19 vaccinated Mongolian participants. Antibodies blocking ACE2-RBD binding across SARS-CoV-2 variants were highest among Pfizer/BioNTech vaccinees, followed by AstraZeneca, Sputnik V, and then Sinopharm vaccinees. Breakthrough infections in June-July 2021 were predominantly the Alpha variant and induced higher blocking antibodies across vaccination groups. |
| تدمد: | 1934-6069 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f968cbcb0fbb483a87a15b9817d23503Test https://pubmed.ncbi.nlm.nih.gov/34861167Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f968cbcb0fbb483a87a15b9817d23503 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19346069 |
|---|